APRE

Aprea Therapeutics, Inc. (APRE) | Rumor.io

Aprea Therapeutics

APRE

Attention (50-day avg)0%

Attention rank (50-day avg)#2,542

Bullish sentiment (50-day avg)100%

Price to earnings ratio0.48

Market capitalization9.5M

Earnings per share-0.94

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-12.6M

Social

What share of all stock conversation is about APRE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 26

Aprea Therapeutics, Inc. (APRE) has seen increased relative volume, with a 6.73x RVOL, and a 10% price move.
The company's clinical progress is being closely watched, with some expecting details of two recent patient successes to be released.
APRE's market capitalization is $13.2M, with a day range of 0.96 – 1.16 and a 52-week range of 0.55 – 1.69.

Generated by AI

Sentiment

Of the messages about APRE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	85% -10.94
Bearish	—	—	—	15% +10.94

Bullish· Feb 2

Analysts predict a "buy" rating with a target price of $4.00 due to the new drug's good safety and potential efficacy.
The company has sufficient cash until 2027, making it an attractive investment opportunity.
A potential move to double digits is expected, with some analysts predicting a target price of $4.00 and others believing the stock could reach $2, $3, or $5.

Bearish· Jan 30

Aprea Therapeutics' ($APRE) price action is heavily manipulated by traders, making its fundamentals irrelevant.
The stock has a history of tanking after each purchase, and shorts are not yet cooked, suggesting further decline.
The company's warrant holders are selling at a 100% premium, while retail investors are losing money due to pump and dump schemes.

Generated by AI

Topics

Of the messages about APRE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	52.67%
Analysts	—	—	0%	13.74%
Macro	—	—	0%	11.45%
Technical Analysis	—	—	0%	22.14%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%

Analysts· Aug 13

Morgan Stanley analyst Jeffrey Hung downgraded Aprea Therapeutics from Equal-Weight to Underweight and lowered the price target from $5 to $3.
RBC Capital analyst Gregory Renza maintained Aprea Therapeutics with a Sector Perform and lowered the price target from $6 to $5.
Analysts have a mildly confident buy consensus for Aprea Therapeutics, with 68% of 5 analysts recommending a buy.

Announcements· Jan 29

Aprea Therapeutics announced a private placement of $5.6 million, issuing 6.29 million shares and warrants at a price of $0.89.
The company reported early clinical proof-of-concept in its ongoing ACESOT-1051 dose-escalation trial, demonstrating a partial response in a patient with advanced solid tumors.
A patient in the trial showed a 50% reduction in target lesion and a greater than 90% decrease in tumor biomarker cancer antigen 125.

Technical Analysis· Dec 9

The 20 MA crossed over the 50 MA, a pattern that has occurred 4 times since August, resulting in an average price increase of ~30%.
The stock is setting up for a potential breakout, with indicators such as MACD crossover, Stoch RSI, and RSI curling up, suggesting a bullish trend.
The stock has the potential to break through resistance and retest its highs, with targets ranging from $9.49 to $10.81, and a current consolidation phase being seen as bullish.

Generated by AI

Community

Of the messages about APRE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	50%	18.83%
Newcomers	—	—	50%	81.17%

Regulars· Feb 23

Aprea Therapeutics priced its offering at $5.25/share, with 1.05M shares sold.
The company's stock price dipped after pricing a $5.5 million underwritten public offering of common stock.
Aprea Therapeutics shares are trading lower after the company announced pricing of a $5.5 million underwritten public offering of common stock.

Newcomers· Aug 26

New users are optimistic about APRE's future performance, with some expecting it to continue its upward trend.
The asset's ability to hold above a certain level is being questioned, with some users wondering if a reverse split (RS) is needed to maintain compliance.
There is speculation about the potential catalysts for APRE's performance, with some users looking to Q4 2026 and 2027 for significant events.

Generated by AI

News

Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs

Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents

1mo agoBarchart.com

Aprea Therapeutics records second consecutive surge, jumping another 22% (APRE:NASDAQ)

1mo agoSeeking Alpha

Lipocine Appoints Michael J. Grissinger to Board of Directors

1mo agoYahoo Finance

Also Discussed

Investors talking about APRE also mention

#	Name	Attention
1	DNA X, Inc.SONM	0%+0
2	TDH Holdings, Inc.PETZ	0%new
3	Ovid Therapeutics Inc.OVID	0%0
4	Enveric Biosciences Inc.ENVB	0%0
5	FRLN - Freeline Therapeutics Holdings plc	——
6	Zivo Bioscience Inc.ZIVO	0%0
7	METX - Meten Holding Group Ltd.	——
8	Context Therapeutics Inc.CNTX	0%0
9	Ensysce Biosciences, Inc. Common StockENSC	0%0
10	RenovoRx, Inc.RNXT	0%0

Aprea Therapeutics, Inc.

Healthcare
Biotechnology

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology and biomarker-defined cancers. The company develops targeted cancer therapies designed to exploit DNA damage response and synthetic lethality pathways, aiming to address vulnerabilities in tumor cells while limiting impact on healthy tissue. Its current pipeline centers on investigational small-molecule programs, including APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, both being evaluated in clinical development for solid tumor indications. Aprea Therapeutics concentrates on oncology research and drug development for cancers with high unmet medical need, supporting its role in the broader market for targeted and precision medicine therapeutics. The company is headquartered in Doylestown, Pennsylvania.

Website

Location

3805 Old Easton Road

Doylestown, PA, 18902

United States

Social

What share of all stock conversation is about APRE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 26

Aprea Therapeutics, Inc. (APRE) has seen increased relative volume, with a 6.73x RVOL, and a 10% price move.
The company's clinical progress is being closely watched, with some expecting details of two recent patient successes to be released.
APRE's market capitalization is $13.2M, with a day range of 0.96 – 1.16 and a 52-week range of 0.55 – 1.69.

Generated by AI

Sentiment

Of the messages about APRE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	85% -10.94
Bearish	—	—	—	15% +10.94

Bullish· Feb 2

Analysts predict a "buy" rating with a target price of $4.00 due to the new drug's good safety and potential efficacy.
The company has sufficient cash until 2027, making it an attractive investment opportunity.
A potential move to double digits is expected, with some analysts predicting a target price of $4.00 and others believing the stock could reach $2, $3, or $5.

Bearish· Jan 30

Aprea Therapeutics' ($APRE) price action is heavily manipulated by traders, making its fundamentals irrelevant.
The stock has a history of tanking after each purchase, and shorts are not yet cooked, suggesting further decline.
The company's warrant holders are selling at a 100% premium, while retail investors are losing money due to pump and dump schemes.

Generated by AI

Topics

Of the messages about APRE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	52.67%
Analysts	—	—	0%	13.74%
Macro	—	—	0%	11.45%
Technical Analysis	—	—	0%	22.14%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%

Analysts· Aug 13

Morgan Stanley analyst Jeffrey Hung downgraded Aprea Therapeutics from Equal-Weight to Underweight and lowered the price target from $5 to $3.
RBC Capital analyst Gregory Renza maintained Aprea Therapeutics with a Sector Perform and lowered the price target from $6 to $5.
Analysts have a mildly confident buy consensus for Aprea Therapeutics, with 68% of 5 analysts recommending a buy.

Announcements· Jan 29

Aprea Therapeutics announced a private placement of $5.6 million, issuing 6.29 million shares and warrants at a price of $0.89.
The company reported early clinical proof-of-concept in its ongoing ACESOT-1051 dose-escalation trial, demonstrating a partial response in a patient with advanced solid tumors.
A patient in the trial showed a 50% reduction in target lesion and a greater than 90% decrease in tumor biomarker cancer antigen 125.

Technical Analysis· Dec 9

The 20 MA crossed over the 50 MA, a pattern that has occurred 4 times since August, resulting in an average price increase of ~30%.
The stock is setting up for a potential breakout, with indicators such as MACD crossover, Stoch RSI, and RSI curling up, suggesting a bullish trend.
The stock has the potential to break through resistance and retest its highs, with targets ranging from $9.49 to $10.81, and a current consolidation phase being seen as bullish.

Generated by AI

Community

Of the messages about APRE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	50%	18.83%
Newcomers	—	—	50%	81.17%

Regulars· Feb 23

Aprea Therapeutics priced its offering at $5.25/share, with 1.05M shares sold.
The company's stock price dipped after pricing a $5.5 million underwritten public offering of common stock.
Aprea Therapeutics shares are trading lower after the company announced pricing of a $5.5 million underwritten public offering of common stock.

Newcomers· Aug 26

New users are optimistic about APRE's future performance, with some expecting it to continue its upward trend.
The asset's ability to hold above a certain level is being questioned, with some users wondering if a reverse split (RS) is needed to maintain compliance.
There is speculation about the potential catalysts for APRE's performance, with some users looking to Q4 2026 and 2027 for significant events.

Generated by AI

Aprea Therapeutics

Social

Aug 26

Bullish· Feb 2

Bearish· Jan 30

Analysts· Aug 13

Announcements· Jan 29

Technical Analysis· Dec 9

Regulars· Feb 23

Newcomers· Aug 26

Aprea Therapeutics to present WEE1 inhibitor trial data in November

Aprea Therapeutics at H.C. Wainwright conference: early data lifts outlook

Aprea Therapeutics reports patent portfolio of 58 patents

Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs

Aprea Therapeutics records second consecutive surge, jumping another 22% (APRE:NASDAQ)

Lipocine Appoints Michael J. Grissinger to Board of Directors

Also Discussed

Aprea Therapeutics, Inc.

Company Information

Location

Aprea Therapeutics to present WEE1 inhibitor trial data in November

Aprea Therapeutics at H.C. Wainwright conference: early data lifts outlook

Aprea Therapeutics reports patent portfolio of 58 patents

Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs

Aprea Therapeutics records second consecutive surge, jumping another 22% (APRE:NASDAQ)

Lipocine Appoints Michael J. Grissinger to Board of Directors

Also Discussed

Social

Aug 26

Bullish· Feb 2

Bearish· Jan 30

Analysts· Aug 13

Announcements· Jan 29

Technical Analysis· Dec 9

Regulars· Feb 23

Newcomers· Aug 26